According to the American Cancer Society in 2020 there will be about 81,400 new cases of bladder cancer in the United States.

At the John Wayne Cancer Institute at Providence Saint John’s Health Center, we treat both early and later stage bladder cancer. Our team is committed to creating a treatment plan that’s as unique as you are.

Below we’ve listed several clinical trials that are at the forefront of the newest therapies. Contact us today to see which trials is best for your condition.

  1. MK-3475-866: A global, randomized phase III study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eligible patients with muscle-invasive bladder cancer (MIBC).
  2. MK-3475-905: A global, randomized phase III study to evaluate perioperative pembrolizumab with radical cystectomy + pelvic lymph node dissection (RC+PLND) versus RC+PLND alone in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC).
  3. MK-7902-011: A global, randomized phase III study to evaluate lenvatinib in combination with pembrolizumab for cisplatin-ineligible participants whose tumors express PD-L1, or in participants ineligible for any platinum-containing chemotherapy regardless of PD-L1 expression, with advanced or metastatic bladder cancer.

Call us at 310-582-7138 or fill out our form and one of our clinical trial oncology nurses will contact you to see if you’re eligible for one of our clinical trials.

  • *Disclaimer. These are not for emergent medical situations. Someone will get back to you within 2-3 business days, but if you are having acute issues please go to the emergency room.